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Pharmaceutical Sciences at Virginia Commonwealth University. 
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Professor, Department of Pharmacotherapy & Outcomes Science 
 
 
 
OBJECTIVES: To assess cost effectiveness of anticoagulant clinics after FDA approval of New 
Oral Anticoagulants (NOACs) for preventing ischemic stroke in Atrial Fibrillation (AF) patients 
in the United States. METHODS: A decision tree was built to compare cost and effectiveness of 
150mg dabigatran twice a day to adjusted dose of warfarin within anticoagulation clinic. The 
analysis was for one year using a societal perspective. The population in this analysis was a 
cohort‎of‎AF‎patients,‎≥‎65‎years‎old,‎with‎a CHADS2 score>2, and no contraindication to 
anticoagulation. RESULTS: The base case analysis showed that changing from warfarin with 
anticoagulant clinic to dabigatran without monitoring resulted in an additional $82,793 per 
QALY saved. Sensitivity analyses found that the model was sensitive to utilities of patients on 
warfarin. CONCLUSION: This study showed that substituting dabigatran for warfarin in this 
population was not within acceptable willingness to pay values for new therapy. 
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Chapter I: Introduction 
Section 1.1: Background 
 
Atrial Fibrillation (AF): 
Atrial fibrillation (AF) is considered one of the most common sustained cardiac arrhythmias in 
clinical practice. Statistics show that it affects more than 2.2 million Americans.
1 
One of the most 
common complications of AF is Ischemic Stroke (IS). Approximately 15 percent of strokes are a 
result of AF.
2
 Independently, AF increases the risk of IS 5 fold among all ages.
3
 
 
Risk of IS increases in AF patients with advancing age, hypertension, heart failure, diabetes 
mellitus, history of previous stroke or Transit Ischemic Attack (TIA),vascular disease, and 
female sex.
 3
 According to the latest report of Heart Disease and Stroke Statistics, the percentage 
of strokes related to AF increases from 1.5% at 50 to 59 years of age to 23.5% at 80 to 89 years 
of age.
3 
Previous stroke or TIA is considered a strong independent predictor of stroke among AF 
patients with a relative risk of 1.9 to 3.7.
4
 AF patients with hypertension and diabetes mellitus 
have a relative risk of stroke of 1.7 compared to non- hypertension and non-diabetics patients.
4 
AF patients with cardiac failure have relative risk of 1.4 for stroke.
4
 
 
There are several indexes that help to estimate stroke risk in patients with AF. The most 
commonly used index is CHADS2 score which is a validated scheme for stratifying stroke risk in 
AF patients.
1,5
  The CHADS2 score is a number from 0 to 6, where 0 is lowest risk and 6 is 
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highest risk. Stroke risk is calculated depending on the following risk factors: congestive heart 
failure history,‎hypertension‎history,‎age‎≥75,‎diabetes‎mellitus,‎and‎history of stroke or TIA 
symptoms. Presentation of each risk factor adds 1 point to the total CHADS2 score with the 
exception of history of a previous stroke which adds 2 points.
6
  
 
AF patients who have experienced a stroke have higher mortality rates.
1
 Moreover; stroke can 
affect‎a‎patient’s‎quality‎of‎life‎as‎it‎may‎cause‎different‎types‎of‎disabilities,‎such‎as‎vision‎
impairment, inability to walk without assistance, cognitive deficits, and depression. Stroke 
complications are associated with socioeconomic burden on both individuals and the healthcare 
system. In the United States, the mean lifetime cost per patient with an IS has been estimated at 
$140,048.
1
 Inpatient care is considered the main cost driver, accounting for 70% of costs in the 
first year after a stroke.
1
 After the first year of survival, costs of lost productivity and 
rehabilitation can be significant. According to the U.S. Centers of Disease Control (CDC), the 
estimated direct and indirect cost associated with stroke in the US 2010 was $53.9 billion 
dollars.
7
  
 
Warfarin 
Warfarin has long been the most common treatment for preventing stroke in AF patients at 
higher risk for stroke (i.e., CHADS2 score‎≥1).‎Warfarin‎is‎a‎Vitamin‎K‎Antagonist (VKA). The 
synthesis of clotting factors II, VII, IX, and X and the anticoagulant proteins C and S depend on 
vitamin K, and warfarin acts as an anticoagulant by antagonizing vitamin K and thus inhibits 
synthesis of these clotting factors.
8‎Warfarin has been used since the 1940’s.9 Studies have 
shown it to be effective in preventing stroke in AF patients and relatively inexpensive.
8 
However, 
warfarin is under-utilized in the general practice. It is estimated that almost one third to one half 
 3 
 
of all eligible AF patients do not receive warfarin.
9
 According to the Agency of Health Care 
Policy and Research, underuse of warfarin in AF patients results in 40,000 preventable strokes in 
the US each year at a cost of $600 million annually.
10
  
 
A major reason for the sub optimal use of warfarin is its narrow therapeutic range and potential 
for negative side effects. Effective treatment with warfarin requires patients to be maintained 
within a narrow International Normalized Ratio (INR) range of 2 to 3. Maintenance of that range 
requires continuous monitoring and potential dosing changes due to pharmacokinetic properties 
of warfarin. The difficulty of warfarin dosing and monitoring is complicated by many drug and 
food interactions. For example, anticoagulation effects of warfarin may decrease when taken 
with food rich in vitamin K such as broccoli, asparagus, or cabbage. Also, warfarin metabolism 
involves CYP450 isozymes, so concomitant administration of any CYP450 inducers like 
phenytoin or cigarette smoking may decrease the effect of warfarin. Inhibitors like acyclovir may 
increase effect of warfarin. These drug and food interactions may influence the pharmacokinetics 
of the drug in the body, or they may worry patients and reduce their adherence behavior.
11
 
Inadequate dosing of warfarin can increase the potential for stroke, while overdosing increases 
risk of bleeding. 
 
Anticoagulation Clinics 
In 1996, Rosendaal reported that extensive monitoring of oral anticoagulation therapy by 
individuals in specialized anticoagulation clinics improves the effectiveness and reduces 
complications associated with oral anticoagulation therapy.
10
 The American College of Chest 
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Physicians emphasized on the important role of anticoagulant clinics in improving quality of care 
of patients on warfarin treatment.
10
 
 
The anticoagulant clinic offers various services in order to enhance health outcomes of patients 
on anticoagulant treatment. It involves conducting necessary laboratory tests, continuous follow 
up for patients on anticoagulant treatment, and patient’s‎education.12 These activities may differ 
between one clinic to another depending on the setting used and clinical standards. The 
anticoagulant clinics are usually delivered by pharmacists or nurses and considered the most 
common service offered by outpatient pharmacists.
13 
 In the United States most of the 
anticoagulant clinics are run by pharmacists. It has been estimated that approximately 60% of 
anticoagulant clinics in US are managed by pharmacists.
14
 
 
Studies have shown that the pharmacist-managed anticoagulant clinics are cost effective 
compared to usual care. Elaine Chiquette et al. concluded that anticoagulation control is 
improved by the pharmacist run anticoagulant clinics and saved $162,058 per 100 patients 
annually.
10
 Despite the effectiveness of these clinics, most warfarin patients are not followed by 
anticoagulant clinics.
15
 Only 30-40% of AF patients on warfarin attend the anticoagulant clinic.
14
 
 
New Oral Anticoagulation Medications 
In recent years, novel anticoagulant agents have entered the US market with the potential to 
dramatically impact anticoagulation clinics and other anticoagulation services.  These 
medications are Dabigatran, Rivaroxaban, and Apixaban.   
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Dabigatran was the first new oral anticoagulation agent approved by FDA in 2010. While 
warfarin works by inhibiting of first step in the coagulation cascade, dabigatran works by 
inhibiting a second step (figure 1.1). Dabigatran etexilate is a reversible direct thrombin 
inhibitor. It inhibits coagulation by preventing thrombin-mediated effects including cleavage of 
fibrinogen to fibrin monomers, activation of factors V, VIII, XI, XIII and inhibition of thrombin-
induced platelet aggregation. 
 
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial investigated 
the efficacy and safety of dabigatran (110mg twice daily, 150mg twice daily) compared to an 
adjusted dose of warfarin in 18,113 AF patients for a period of 2 years.
16
 Based on this study, 
dabigatran 150mg was found to be better in preventing strokes compared to warfarin (P <0.001), 
while the 110mg dose was similar to warfarin (P <0.35). However regarding the safety profile 
dabigatran 150 mg had higher risk for Gastrointestinal (GI) bleeding (P <0.001) compared to 
warfarin, while 110mg was similar to warfarin (P = 0.43). Both doses showed significantly lower 
Intracranial Hemorrhage (ICH) compared to warfarin (P <0.001). For the risk of developing 
Myocardial infarction (MI), dabigatran 150 mg showed higher risk compared to warfarin (P = 
0.048), while 110 mg had similar risk as warfarin (P = 0.07).  
 
Based on these results, only the 150 mg dose was approved by FDA. In this study dabigatran has 
not been studied in patients with severe renal impairment, as patients with a Creatinine Clearance 
(CrCl) less than 30 mL/min were excluded from RE-LY. FDA approved a dose of 75 mg of 
dabigatran for patients with renal impairment. Dabigatran is approved for stroke prevention in 
 6 
 
AF patients, treatment and prevention for deep vein thrombosis (DVT) and pulmonary 
embolism. 
 
Recently on May 2014, FDA had reported the results of a study conducted by them on more than 
134,000 Medicare patients.
17
 In this study they measured the safety and effectiveness profile of 
dabigatran compared to warfarin in almost similar population as the RELY trial. Their findings 
were consistent with the RELY trial, except for probabilities of developing MI with dabigatran 
150 mg and warfarin. In contrast to RELY trial, this study had reported that there is no 
significant difference in the probabilities of developing MI between two treatment options.  
 
Following dabigatran, FDA approved rivaroxaban in 2011 as a treatment to prevent stroke in AF 
patients. Rivaroxaban is a factor Xa inhibitor, and it prevents stroke by inhibiting platelet 
activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa.  
 
The efficacy and safety of rivaroxaban were evaluated in Rivaroxaban Once Daily Oral Direct 
Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and 
Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial.
18
 It compared rivaroxaban 20 mg once 
a day (reduced to 15 mg a day for patients with a CrCl of 30 to 49 mL/min) to an adjusted dose 
of warfarin in 14,269 patients with AF for an average period of 1.6 years. Rivaroxaban was 
shown to be similar to warfarin in preventing stroke (P =0.12) and MI (P = 0.12). It was found to 
have superior effect in reducing ICH compared to warfarin (P =0 .02).  However, for GI 
bleeding, rivaroxaban had significantly higher risk compared to adjusted dose of warfarin (P 
<0.001). 
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A once daily dose of 20mg of rivaroxaban was approved by FDA for patients with CrCl >50 
mL/min and a 15mg once daily dose for patients with a CrCl between 15–50 mL/min to prevent 
stroke in AF patients. Moreover, FDA approved rivaroxaban for preventing stroke for post-
operative thrombophylaxis Deep Vein Thromboembolism (DVT), and Pulmonary Embolism 
(PE). 
 
Apixaban is a factor Xa inhibitor approved by FDA in 2013 for stroke prevention in AF patients. 
It prevents stroke with a similar mechanism of action to rivaroxaban.  
 
In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation 
(ARISTOTLE) trial, the efficacy and safety of apixaban was assessed.
19
 Apixaban was found to 
be superior to warfarin for preventing stroke (P = 0.01). GI bleeding and MI was similar to 
warfarin (P= 0.37 for both events). Risk of ICH was significantly lower in apixaban patients 
compared to warfarin (P<0.001). Apixaban 5mg twice daily was approved by FDA to prevent 
stroke in patient with AF, treatment and prevention for DVT and pulmonary embolism. 
 
A 2012 study looking at the potential for switching warfarin to new oral anticoagulants (NOACs) 
found that more than 60% of patients in Johns Hopkins anticoagulation clinics could do so.
20
 
 
Despite the effectiveness and safety of NOACs compared to warfarin, they face challenges to 
replace warfarin. NOACs are considered to have higher acquisition cost compared to warfarin. 
NOACs are also mainly excreted by kidney and may not be appropriate in renal impairment 
 8 
 
unlike patients treated with warfarin. Apixaban may be a relatively safer option with renal 
impairment as it is excreted via multiplies pathways. Furthermore, there is little evidence of the 
long term effect of NOACs, and there is no antidote to reverse effect of these drugs, unlike 
warfarin. So adoption and usage for NOACs may depend heavily on its perceived economic 
value.  
Section 1.2: Objectives 
1. Calculate costs and Quality Adjusted Life Years (QALYs) associated with treatment of AF 
patient with dabigatran 150mg BID and adjusted dose of warfarin within pharmacist-
managed anticoagulant clinic. 
2. Build a decision tree model with the 2 therapeutic approaches and map out associated 
outcomes. 
3. Evaluate the cost effectiveness of dabigatran 150mg BID compared to adjusted dose of 
warfarin within pharmacist-managed anticoagulant clinics. 
Section 1.3: Rationale 
Studies addressing the cost effectiveness of NOACs compared to warfarin have used similar 
models and outcome measurements. Most of the previous studies built Markov model with 
almost similar health states and time horizons. Moreover, they only used single source as a 
reference for their probabilities.  
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Furthermore, there were limited studies that account for INR control level in their cost 
effectiveness analysis. There is lack of studies that directly assessed cost effectiveness of 
NOACs to warfarin treatment within anticoagulant clinic settings. 
 
Because the dabigatran was the first NOACs introduced into the US market and so it is assumed 
to be well utilized, it was chosen in the present analysis to represent NOACs. Moreover there are 
more available data regarding dabigatran compared to other NOACs. 
 
Based on the available literature, this is the first study that compared directly between dabigatran 
and warfarin treatment within pharmacist-managed anticoagulant clinic. This study will enable 
us to answer the question about the future of these clinics after introduction of NOACs into the 
market, especially as they do not require monitoring like warfarin. Finally in this study, we tried 
to obtain probabilities data from a secondary source and test it in the sensitivity analysis. 
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Figure1.1: Mechanism of action of oral anticoagulants 
21
 
 11 
 
Chapter II: Literature review and discussion of decision analysis 
Section 2.1: Literature review 
 
In order to assess cost effectiveness of NOACs compared to warfarin in usual care setting and 
anticoagulant clinic, we need to evaluate what is there in the literature. This was done in two 
steps. First, studies that looked at the effectiveness and cost effectiveness of warfarin in usual 
care versus anticoagulant clinic were evaluated. Based on the literature, we hypothesized that 
anticoagulant clinic is more cost effective compared to usual care. 
 
Then, the effectiveness and cost effectiveness of NOACs versus warfarin in anticoagulant clinic 
were assessed. This part was done under the assumption that patients treated with NOACs do not 
need a follow up in an anticoagulant clinic. According to study done by Lee, et al. that looked at 
adherence rate and clinical outcomes of dabigatran in anticoagulant clinic versus usual care, they 
concluded that neither the adherence rate nor the therapeutics outcomes differed between patients 
in the two groups.
22
 So this study can support the assumption that NOACs do not required 
monitoring by anticoagulant clinic in order to improve patient outcomes.  
 12 
 
Section 2.2: Systematic literature review on the effectiveness and cost effectiveness of 
pharmacist-managed anticoagulant clinic compared to usual care 
A systematic literature review was conducted on October 2014 using PubMed/MEDLINE, 
CINAHL, ECONLIT and IPA. The search terms were combinations of: ("Warfarin" AND 
"Anticoagulant clinic") AND ("Cost" OR "Costs"), ("Anticoagulant clinic" AND "pharmacy"), 
("pharmacist managed Anticoagulant clinic"), ("pharmacist managed Anticoagulant service"). 
Titles and abstracts from search result articles were screened for using the following inclusion 
criteria and exclusion criteria: 
Inclusion criteria: 
1. Assess cost-effectiveness of pharmacist-managed anticoagulant clinic. 
2. Assess effectiveness of pharmacist-managed anticoagulant clinic. 
3. Published in English.  
4. Addressed patient with Atrial Fibrillation (AF). 
5. Abstract is available. 
Exclusion criteria: 
1. Studies not conducted in the United States. 
2. Studies compared aspirin or heparin to warfarin. 
 
The search of the databases revealed a total of 1,293 articles. After eliminating duplicates and 
applying inclusion and exclusion criteria, 57 research articles remained. 
23-79
 Out of these 57 
articles, 6 articles were chosen to be discussed as they were the most recent studies, and had 
more updated information. Moreover, these chosen articles were the most relevant to the 
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inclusion criteria, while the other articles were either focusing only on the cost of anticoagulant 
clinic compared to usual care or did not include a comparison group.
29,31,40,54,61,72
 
Literature Summary 
Most articles revealed by the literature review looked at the effectiveness of an anticoagulant 
clinic compared to usual care for patients receiving warfarin therapy. Most did not indicate a 
specific diagnosis for treated patients; including patients with AF and other indication who are 
on warfarin.  
Five articles compared the effectiveness of anticoagulant clinics compared to usual care, and 1 
article was a cost-effectiveness analysis of an anticoagulant clinic compared to usual care 
(Tables 2.1 and 2.3).  
 
One of the 5 effectiveness articles, by Nichol et al. (2008), specified AF patients.
61
 The study 
was a retrospective observational cohort that used claim data of a physician group practice. 
Using International Classification of Diseases Ninth Revision code (ICD-9), they identified AF 
patients on warfarin and having more than 1 INR test between March 2001 to March 2004. 
Patients were excluded if they had more than a one year gap between 2 INR tests.  
 
Usual care in this study consisted of patients treated by a care team which included primary care 
physicians and nurses but which had no standardized protocol of care. Patients treated in the 
anticoagulant clinic were managed by similar care team guided by a standardized warfarin 
management protocol. Any patients treated with warfarin were eligible to be referred to an 
anticoagulant clinic. Patients included in this study were either treated with usual care or 
attended an anticoagulant clinic, with no crossover between two groups. 
 14 
 
 
The outcome measures used to assess quality were time spent in therapeutic range (INR 2-3) and 
time to first occurrence of major bleeding or stroke. A t-test compared time spent in therapeutic 
range between the 2 groups, and a Kaplan Meier survival analysis compared rates of bleeding or 
stroke.  
 
The study found that the 351 patients in the anticoagulant clinic spent significantly more time in 
therapeutic range compared to the 756 patients in the usual care group. Rates of major bleeding 
and stroke were lower, but not statistically so, in the anticoagulant clinic group compared to 
usual care.  
 
Some studies in the literature have assessed the effectiveness of anticoagulant clinics managed 
by pharmacists compared to usual care; but are not specific to AF patients (i.e. several 
indications of warfarin). Chiquette E, et al. compared 142 newly treated anticoagulant patients in 
usual care to 176 newly treated patients in an anticoagulant clinic.
31
 The outcome measures were 
anticoagulant control (time within therapeutic range), bleeding, thromboembolism events, and 
cost of hospitalization and emergency room (ER) visit. Based on the results of this study, 
patients treated in an anticoagulant clinic had lower rates of significant bleeding, major to fatal 
bleeding, thromboembolism events, and significantly lower annual rates of hospitalization and 
ER visits related to warfarin treatment. 
 
A recent article by Hall, et al. in 2011 evaluated differences in health care expenditures and the 
clinical outcomes between usual care and a pharmacist-managed anticoagulant clinic.
40
 Using 
 15 
 
data from the University of Pittsburg Medical Center (UPMC), they reviewed 175 patients in 
each group of which 60% were AF patients. They looked at cost, medical outcomes, and patient 
compliance. Direct, overall medical and operational costs were included when measuring costs. 
The therapeutic outcomes were adverse events, percentage of INR within therapeutic range, time 
spent within therapeutic range, and ER visits. Patient compliance was measured by calculating 
the Medication Possession Ration (MPR). Similar to Chiquette E, et al., authors reported that 
patients in the anticoagulant clinic had significantly higher therapeutic INR rates and spent 
longer time in this range compared to usual care. Anticoagulant clinic patients experienced fewer 
adverse events and ER visits. 
 
Locke, et al. (2005) explored the difference in adverse events related to warfarin treatment in 
pharmacist-managed anticoagulant clinics and usual care.
54
 Using a before and after research 
design, 420 patients in a community hospital outpatient anticoagulant clinic were discontinued 
from an anticoagulation clinic program and assigned to usual care. Authors found that patients 
discontinued from the clinic experienced significantly more adverse events related to warfarin 
treatment compared to those treated with pharmacist-managed anticoagulant clinic. 
 
One study was less compelling for the benefits of an anticoagulation clinic in managing warfarin 
therapy. It compared patient outcomes in pharmacist managed anticoagulant clinic (n=41) to 
usual care (n=75).
29
 In contrast to previous studies, no statistical significant difference was 
detected in the rate of adverse events or ER visits between two groups, although the percentage 
of anticoagulant clinic patients within therapeutic ranges was significantly higher. The absent of 
statistical significant can be due to the small sample size in each groups.  
 16 
 
 
A study by Sullivan et al. evaluated the cost-effectiveness of a pharmacist-managed 
anticoagulant clinic compared to usual care for AF patients with high risk of stroke.
72
 The 
analysis used a semi-Markov model to compare usual care and clinic services using a societal 
perspective. A cohort of AF patients similar to the SPORTIF (Stroke Prevention using Oral 
Thrombin Inhibitor in atrial Fibrillation) III and V trials was used.  
 
They found that anticoagulation monitoring services improved effectiveness by 0.057 QALYs 
and cost $US2100 less, and therefore dominated usual care. Their sensitivity analysis found that 
the results were sensitive to the risk of all strokes and systemic embolic events associated with 
usual care, but were robust with other input variables. Moreover, a Monto Carlo simulation 
showed robust results in favor of anticoagulation management services dominating usual care in 
91% of possible circumstances. 
 
In summary, the literature suggests that AF patients receiving warfarin and managed in 
anticoagulation clinics have better therapeutic control over their INRs, less adverse events, fewer 
health care visits for warfarin related causes, and lower costs of care. 
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Section 2.3: Systematic literature review on the effectiveness and cost effectiveness of 
NOACs compared to warfarin in pharmacist-managed anticoagulant clinic 
Systematic literature review was conducted on October 2014. PubMed/MEDLINE, CINAHL, 
ECONLIT and IPA were used for literature search with combination of the search terms: 
("Warfarin") AND ("Anticoagulant" OR "Anticoagulants") AND ("Cost" OR "Costs"), 
("Warfarin") AND ("Apixaban" OR "Dabigatran" OR "rivaroxaban") AND ("Cost" OR "Costs"), 
("Anticoagulant clinic") AND ("NOACs" OR "Apixaban" OR "Dabigatran" OR "rivaroxaban"). 
Titles and abstracts were first screened for inclusion criteria and exclusion criteria. The inclusion 
and exclusion criteria that were applied are defined as the following: 
Inclusion criteria: 
1. Assess effectiveness of NOACs compared to warfarin. 
2. Assess cost-effectiveness of NOACs compared to warfarin. 
3. Published in English.  
4. Addressed patient with AF. 
5. Abstract is available. 
Exclusion criteria: 
1. Studies not conducted in the United States. 
2. Studies compared NOACs with aspirin or heparin. 
 
A search of the 4 databases revealed a total of 2,989 articles. After eliminating duplicates and 
applying inclusion and exclusion criteria, a total of 21 research articles were found. 
22,80-99
 Out of 
21 articles 13 articles were chosen to be discussed, as they were most relevant to the search 
criteria, and available.
80,83,84,87,88,90-96,98
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Literature Summary 
Thirteen articles were identified as relevant to this research. Five compared effectiveness and 
safety of NOACs to warfarin (Table 2.2).
80,87,90,96,98
  The 8 remaining articles assessed cost 
effectiveness of NOACs compared to warfarin. 
83,84,88,91-95,97
 
 
One of the 5 effectiveness studies compared all three NOACs to warfarin.
98
 In this study, the 
authors searched a clinical trials database and found 3 large clinical trials comparing NOACs to 
warfarin (ARISTOTLE for apixaban, RELY for dabigatran, and ROCKET-AF for rivaroxaban). 
98
 Almost similar inclusion/exclusion criteria were used for all three trials.  Efficacy was 
determined by rates of developing stroke or Systematic Embolism (SE). Safety was measured in 
the RELY and ARISTOTLE studies by major bleeding events, while the ROCKET-AF trial 
measured major and non-major bleeding. The analysis indicated that there were no significant 
differences in efficacy between the 3 NOACs. Regarding safety profile, apixaban showed a 
significantly lower rate of major bleeding compared to dabigatran and rivaroxaban. No 
significant difference between the 3 NOACs was found in all-cause mortality. Overall, the 3 
NOACs produced almost similar effects in reducing stroke in AF patients with higher risk of 
stroke, however, the apixaban was the safest. 
 
The remaining 4 studies compared the effectiveness of apixaban to warfarin by using the data 
from the ARISTOTLE trial. Amin et al. estimated the real world rate of stroke and bleeding of 
apixaban in AF patients.
80
 Authors used a Medco claims database to identify AF patients with 
CHADS2 score‎≥1‎and‎treated‎with‎warfarin.‎They‎calculated‎rate‎of‎stroke‎and‎bleeding‎
associated with warfarin. By using the Relative Risk Reduction (RRR) from ARISTOTLE trial, 
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they estimated events that can be avoided if apixaban was used instead of warfarin in the real 
world. The analysis showed that event rates associated with warfarin were higher in the real 
world compared to ARISTOTLE trial, and the clinical benefit of apixaban might be greater in the 
real world compared to a clinical trial. However, this is an extrapolation of results from the 
clinical trial and so may not reflect the true apixaban effect in the real world practice. Further 
studies using real world data are needed. 
 
In addition to these articles, the literature review revealed 8 studies that evaluated cost-
effectiveness of NOACs compared to warfarin (Table 2.3).
83,84,88,91-95,97
  There were a lot of 
similarity in the method and model building in the 8 studies. They all used Markov models with 
almost similar health states: well, ICH, Extracranial Hemorrhage (ECH), IS, MI, minor bleeding, 
and death. Cost/QALY was the outcome measure in all of the 8 studies. The analysis was either 
done from societal perspective
83,88,91-93
 or US payer/Medicare perspective
84,94,95,97
 . The input 
transition probabilities were obtained mainly from the three major clinical trials (ARISTOTLE, 
RELY, ROCKET-AF). The populations of all the 8 studies were chosen to be similar to clinical 
trials.  
 
Overall, there were 2 studies that assessed cost effectiveness of all the 3 NOACs compared to 
warfarin in one model.
83,91
 The literature mostly suggested that NOACs are more cost effective 
compared to warfarin. Harrington, et al. found that all the 3 NOACs produced a greater QALY 
compared to warfarin.
91
  At willingness to pay threshold of $50,000 per QALY gained, all the 3 
NOACs are cost effective compared to warfarin. However, a study done by Canestaro, et al. 
found that at a willingness to pay of $100,000 only the apixaban is cost effective compared to 
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warfarin, although all of the 3 NOACs may produce higher efficacy relative to warfarin.
83
 
Despite that these 2 studies were using similar models, the Harrington model did not account for 
ECH as health state and that can explain why the result was favorable to all of the 3 NOACs.  
 
The literature review revealed two studies that evaluated specifically cost effectiveness of 
apixaban compared to warfarin. Both studies found that apixaban is a cost effective strategy 
relative to warfarin.
92,94
 The cost data of apixaban were different in the two studies as the 
apixaban was not yet approved in the US market at the time of the analyses. One study used the 
UK price of apixaban
92
, while the other study assumed it had a similar cost as dabigatran.
94
  
Rivaroxaban cost effectiveness was compared to warfarin in a study by Lee et al.
95
 The authors 
reported that rivaroxaban has a higher cost and higher QALY. The base case analysis revealed 
that rivaroxaban is cost effective compared to warfarin from Medicare perspective with an ICER 
value lower than willingness to pay of $50,000 per QALY gained. 
 
Three studies evaluated cost effectiveness of dabigatran versus warfarin.
84,88,93,97
  Kamel, et al. 
found that dabigatran is cost effective, unless the INR is well control with warfarin treatment.
93
 
A study by Freeman, et al. was done before dabigatran was approved in US market, so they used 
the UK price of the dabigatran in their analysis.
88
 The base case analysis revealed that dabigatran 
is cost effective compared to warfarin; however this result was sensitive to the cost of 
dabigatran.
88
 Clemens, et al. looked at cost effectiveness of dabigatran in different age groups 
(patients‎<75‎years‎old,‎≥75 years old, and all patients). The authors found that dabigatran is cost 
effective regardless age group.
84
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In summary, the literature indicates that NOACs are more effective and more costly compared to 
warfarin, and that the cost effectiveness of NOACs depends on level of INR control with 
warfarin treatment.  
Section 2.4: Gaps in Literature 
This literature review found that it is not clear whether anticoagulation clinics are needed any 
longer after introduction of NOACs. In general, warfarin is less cost effective using clinical trial 
data but it is not clear if similar results will be seen in regular practice settings. It is also not clear 
whether anticoagulation clinics or similar intensity services were used in clinical trials. In 
addition, the costs of providing anticoagulation services were not adequately described in the 
studies.  Moreover, all the studies had used one source to obtain the probabilities for each event.  
 
Finally, no study clearly investigates how patients might benefit from an anticoagulant clinic if 
they receive NOACs. So this study is the first study that looked at cost effectiveness of NOACs 
compared to warfarin in anticoagulant clinic. 
 
 
 
 
 
 
 22 
 
Section 2.5: Discussion of decision analysis 
Based on the literature review, the treatment with warfarin appears to be more cost effective in 
anticoagulant clinics than usual care. The value of these clinics with the availability of NOACs is 
not clear, so an economic model is needed to compare between patients treated with warfarin in 
anticoagulant clinic versus NOACs. Dabigatran was chosen in this analysis to represent NOACs, 
as it was the first one introduced into the US market and so assumed to be well utilized in the 
healthcare facilities. 
 
A decision tree model will enable us to evaluate the cost effectiveness of warfarin within 
anticoagulant clinics compared to 150 mg BID of dabigatran within time period of 1 year. The 
decision tree was chosen to model the present analysis due to simplicity and lack of data 
regarding long term safety and efficacy profile of dabigatran. The tree will assess most common 
outcomes associated with each treatment strategy which are: well, IS, ICH, MI, GI bleeding, 
dyspepsia, and death. The probabilities of each event will be mainly obtained from RELY 
clinical trial or published literature.  
 
In any cost effectiveness analysis, it is very important to clearly define the base case population. 
In this study the population of interest is AF patients, age >65, with CHADS2 score‎≥‎2,‎and‎no 
contraindication to anticoagulation.‎Patients‎with‎creatinine clearance of < 30 ml per minute or 
with active liver disease will be excluded from the study population.  
 
It is crucial to state the perspective that the study will take, as it can affect types of costs included 
in evaluation. In this study the cost effectiveness of dabigatran compared to warfarin within 
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anticoagulant clinic was assessed from a societal perspective. The decision tree will help to map 
up all the resource utilized by each outcome (figure 2.1). The resources utilized were physician 
visits, hospital admissions, INR monitoring and anticoagulant clinic visits with warfarin 
treatment. 
 
Various sensitivity analyses were carried out due to parameter and input uncertainty. Examples 
of parameter uncertainty include probabilities of safety of each treatment strategy and cost of 
anticoagulant clinic. 
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Figure 2.1: Schematic representation of the decision model 
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Table 2.1: Included articles from summary of literature comparing effectiveness of anticoagulant clinic to usual care 
 
 
 
  
Authors/Year Primary measures Patient 
characteristics  
Data source Author’s conclusion 
Nichol et al.
61
 (2008) -Time in therapeutic 
range 
- Time to first bleeding 
event or stroke 
AF patients  Medical and 
pharmaceutical claims 
data from Sharp Rees-
Stealy (SRS) physician 
group 
Anticoagulant clinic had positive impact on 
anticoagulation management. 
Chiquette et al.
31
 
(1998) 
-Anticoagulation 
control 
-Development of 
bleeding or stroke 
-Cost of hospitalization 
and ER visits 
All patients treated 
with warfarin  
University healthcare 
system 
Pharmacist run anticoagulant clinic 
improved anticoagulation control, reduced 
rate of bleeding and stroke, and reduced 
hospitalization and ER visit costs.  
Hall et al.
40
 (2011) -Health care 
expenditure 
-Therapeutic outcomes 
All patients treated 
with warfarin   
University of Pittsburgh 
Medical Center 
Pharmacist run anticoagulant clinic reduced 
health care expenditure and improved 
therapeutics outcomes. 
Locke et al.
54
 (2005) Number of adverse 
events related to 
anticoagulation 
treatment 
All patients treated 
with warfarin   
St.‎Joseph’s‎Medical‎
Center 
Pharmacist managed anticoagulant clinic 
reduced adverse events related to warfarin.   
Chamberlain et al.
29
 
(2001) 
-Anticoagulation 
control 
- ER visit and 
inpatients admission 
related to  stroke or 
bleeding 
 
All patients treated 
with warfarin  
Family Medicine of 
Southwest Washington 
Patients treated in anticoagulant clinic had 
better anticoagulation control, however, 
there are no statistical significant different 
in rate of adverse events  
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Table 2.2: Included articles from summary of literature of effectiveness of NOACs 
* CHA2DS2VASc: score scale for AF patients with stroke risk 
** HAS-BLED scores: score scale to estimates major bleeding risk for patients on anticoagulant 
Authors/Year Primary measures Population 
characteristics 
Source data  Author’s conclusion 
Apixaban 
Amin et al.
80
 (2013) Real world rate of stroke 
and major bleeding 
associated with apixaban 
AF patients with CHADS2 
score‎≥1 
U.S. commercial and 
Medicare health plans 
(Medco claims database) 
Apixaban might have a 
better impact in real world 
relative to warfarin 
Easton et al.
87
 (2012) Efficacy (stroke or SE) and 
safety (major bleeding) 
profiles 
AF patients with and 
without previous stroke or 
TIA 
ARISTOTLE trial Absolute benefit of 
apixaban is higher in 
patients with previous 
stroke compared to 
warfarin 
Granger et al.
90
 (2011) Efficacy (stroke or SE) and 
safety (major bleeding and 
death from any cause) 
profiles 
AF patients with at least 
one additional risk factor 
for stroke 
ARISTOTLE trial Apixaban had lower 
stroke, SE, major bleeding, 
and mortality compared to 
warfarin 
Lopes et al.
96
 (2012) Efficacy (stroke or SE) and 
safety (major bleeding) 
profiles according to 
patients’‎CHADS2, 
CHA2DS2VASc*, and 
HAS-BLED scores** 
AF patients with CHADS2 
score‎≥1 
ARISTOTLE trial Apixaban had better safety 
and efficacy profiles 
compared to warfarin 
regardless stroke risk 
index 
All NOACs 
Schneeweiss et al.
98
 (2012) Efficacy (stroke or SE) and 
safety (major bleeding) 
profiles 
AF patients with a 
CHADS2 score‎≥3 
RELY, ROCKET-AF , 
ARISTOTLE trials 
There are non-significant 
differences in efficacy 
measures between 3 
NOACs, but apixaban had 
lower bleeding risk 
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Table 2.3: Included articles from summary of literature of cost effectiveness analysis 
Authors/Year Primary 
comparisons 
Population 
characteristics 
Model Time 
horizon 
Perspective Model results  Author’s conclusion 
Anticoagulant clinic 
Sullivan et al.
72
 
(2006) 
Usual care 
vs. pharmacist-
managed 
anticoagulation 
monitoring 
service 
Cohort of 70 years 
old AF patients 
with higher risk of 
stroke  
Semi-
Markov 
model 
10 years Society Anticoagulation 
services enhanced 
effectiveness by 
0.057 QALYs and 
cost $US2,100 
less 
Anticoagulation 
management service is 
cost-effective compared to 
usual care 
Dabigatran 
Kamel et al.
93
 
(2012) 
Dabigatran 150 
mg  twice-daily 
vs. 
adjusted dose 
warfarin (INR 
range 2-3) 
Cohort of AF 
patients‎aged‎≥70‎
years 
history of  stroke 
or TIA, and no 
contraindication 
to anticoagulation 
Markov 
model 
20 years Society Dabigatran provided 
additional 0.36 
QALYs with 
cost of $9,000 
(ICER of $25,000) 
Dabigatran is cost effective 
compared to warfarin for 
stroke prevention in AF 
patients with history of 
stroke or TIA 
Freeman et al.
88
 
(2011) 
Dabigatran 110 
mg  twice, daily 
vs. 
dabigatran 150 
mg  twice, daily 
vs. 
adjusted dose 
warfarin  
Cohort of AF 
patients‎≥65‎years‎
with CHADS2 
score ≥‎1, and no 
contraindications 
to anticoagulation 
Markov 
model 
Lifetime Society ICER of 150 mg 
dabigatran was 
$45,372  per QALY, 
and $51,229 per 
QALY for 110mg 
dabigatran. 
Dabigatran 150mg is cost-
effective compared to 
warfarin  
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Authors/Year Primary 
comparisons 
Population 
characteristics 
Model Time 
horizon 
Perspective Model results  Authors conclusion 
Dabigatran  
Clemens et al.
84
 
(2014) 
Dabigatran 150 
mg twice daily 
vs. warfarin 
AF patients at age 
<75 and at age 
≥75‎ 
Markov Lifetime US Medicare 
payer 
ICER was $52,773, 
$65,946, and 
$56,131 for cohorts 
<75,‎≥75,‎and‎All‎
respectively 
Dabigatran is cost-effective 
compared to warfarin 
regardless age group 
Rivaroxaban 
Lee et al.
95
 
(2012) 
Rivaroxaban 20 
mg/day vs. 
adjusted dose 
warfarin  
Cohort of AF 
patients‎≥65years‎
old, CHADS2 
score of 3, no 
contraindications 
to anticoagulation 
Markov  Lifetime US Medicare 
payer 
The ICER of 
rivaroxaban was 
$27,498 per QALY 
Rivaroxaban is cost– 
effective compared to 
warfarin for stroke 
prevention in AF patients 
Apixaban 
Lee et al.
94
 
(2012) 
Apixaban 5mg 
twice daily vs. 
adjusted dose 
warfarin  
Cohort of AF 
patients‎≥65years‎
old, CHADS2 
score of 2.1, no 
contraindications 
to anticoagulation 
Markov Lifetime Medicare Apixaban provided 
additional 0.34 
QALYs and 
cost $2,633 less than 
warfarin 
Apixaban is cost-effective 
alternative to warfarin 
Kamel et al. 
92
(2012) 
Apixaban 5mg 
twice daily vs. 
adjusted dose 
warfarin  
Cohort of AF 
patients  of 70 
years old, with 
history of stroke, 
and no 
contraindications 
to anticoagulation  
Markov  20 years Society  The ICER for 
apixaban was 
$11,400 per QALY 
Apixaban is cost-effective 
compared to warfarin 
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Authors/Year Primary 
comparisons 
Population 
characteristics 
Model Time 
horizon 
Perspective Model results  Authors conclusion 
NOACs 
Harrington et 
al.
91
 (2013) 
Apixaban 5 mg 
vs. dabigatran 
150 mg vs. 
rivaroxaban 20 
mg 
vs. adjusted 
dose warfarin 
Cohort of AF 
patients age 70 
year old, with 
CHADS2 ≥1, 
renal CrCl ≥50 
mL/min, and no 
contraindications 
to anticoagulation 
Markov  Lifetime Society Compared with 
warfarin, apixaban 
resulted in an 
additional 0.5 
QALYs at a cost of 
$7,513, and ICER 
of $15,026 per 
QALY  
NOACs are all cost-
effective compared to 
warfarin 
Canestaro et 
al.
83
 (2013) 
Apixaban 5 mg 
vs. dabigatran 
150 mg vs. 
rivaroxaban 20 
mg 
vs. adjusted 
dose warfarin 
Cohort of AF 
patients  of 70 
years old, with 
mean CHADS2 of 
2, and no 
contraindications 
to anticoagulation 
Markov  Lifetime Society  ICER compared 
with warfarin, for 
dabigatran, 
rivaroxaban, and 
apixaban are 
$140,557, $111,465, 
and $93,062 per 
QALY gained, 
respectively 
At willingness to pay value 
of $100,00, apixaban is the  
cost effective strategy 
compared to warfarin and 
other NOACs 
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Chapter III: Method 
 
Economic evaluation of warfarin in anticoagulant clinic versus dabigatran was done by following 
the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) guideline.
100
 
Section 3.1: Model 
In order to evaluate cost effectiveness of warfarin in anticoagulant clinic to dabigatran, a 
decision tree model was built. Figure 3.1 illustrates the model. There are 2 possible alternatives 
that a patient with AF might be treated with: adjusted warfarin dose with INR 2-3 in a 
pharmacist-managed anticoagulant clinic or 150mg BID of Dabigatran. Each treatment option 
might result in one of the following health states:  well (with no complication), IS, ICH, GI 
bleeding, MI, dyspepsia, or death from any cause. These health states were chosen in this model 
as they were the most common complications reported in the RELY clinical trial and highly 
expensive to treat.
16
 Each complication can either be treated or lead to patient death except for 
dyspepsia.  
The analysis was conducted from the societal perspective as it is consider appropriate for our 
outcome measure (QALY). The reason behind conducting such analysis was to assist decision 
makers to choose best anticoagulant strategy for AF patients. The target population of this 
analysis was similar to the RELY trial population, which was cohort of AF patients,‎≥‎65‎years 
old, with mean CHADS2 2.1, and no contraindication to anticoagulation. Patients with CrCl <30 
mL/min and active liver disease were excluded from study population. 
 31 
 
The time horizon of the analysis was 1 year as probabilities reported in the RELY trial were 
annual and because the period was sufficient to assess effectiveness and identify complications.  
 
Outcome measures included in this study were reported in 2014 $US costs, QALYs, Incremental 
Cost Effectiveness Ratios (ICERs), and Net Monetary Benefit (NMB). The primary measure for 
treatment effectiveness was QALYs saved. QALY is common measure of effectiveness that 
takes into account the quantity of years lived adjusted to its quality.
101
 It has been recommended 
by the panel on cost-effectiveness in Health and Medicine as the preferred outcome measure.
101
 
To calculate QALY, we multiply years lived by coefficient (between 0-1) which corresponds to 
quality of life, such as utilities. For example, the QALY for 1 year equals utility of health state of 
patient multiply by 1. The most common utility measures are time trade off (TTO), standard 
gamble (SG), rating scale (RS), and health state classifications system such as EQ-5D.
102,103
 in 
our analysis, utility of patients can be affected by the health state and type of anticoagulant 
therapy. All analyses were done using TreeAge Pro 2014 software (Appendix A). 
Several assumptions were made in the model:  
1. Patients were assumed to be similar to those in the RELY clinical trial.16 The population 
in this study were assumed to be AF patients with at least one of the following 
conditions:  
a. Previous stroke, TIA, or SE. 
b. Age‎≥65‎years‎with diabetes mellitus, Coronary Artery Disease (CAD), or 
hypertension.  
c. Left Ventricular Ejection Fraction (LVEF) <40%. 
d. Age‎≥75‎years. 
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e. Patients with symptomatic heart failure, New York Heart Association (NYHA) 
Class‎≥2‎within‎at‎last‎6‎months.‎ 
2. Population of the study assumed to have mean CHADS2 score of 2.1, similar to the 
RELY trial. 
3. Probabilities of events for patients treated with warfarin and attending anticoagulant 
clinic were assumed to be similar to patients treated with warfarin in RELY clinical trial. 
This assumption was made as the patients in the RELY were monitored continuously 
almost similar to the anticoagulant clinic setting.
16
 
4. The dose of warfarin was assumed to be 5mg once daily for the cost calculation. 
5. Generic warfarin was used.  
6. Patients on warfarin were assumed to have 1 INR test monthly. 
7. Cost of fatal IS, ICH, GI bleeding was assumed to be similar to the cost of death, due to 
the lack of ICD 9 or DRG code. 
8. Patients develop the event once through the study period. 
9. Patients treated with dabigatran and who develop major bleeding (GI bleeding or ICH) 
were assumed to discontinue treatment, and replace it with rivaroxaban 20 mg once daily. 
This assumption was made according to different bleeding and anticoagulation 
management guidelines. They stated that when the patient develops bleeding with 
dabigatran then it should be discontinued immediately and substituted it with another 
anticoagulant. Rivaroxaban was chosen as it has advantage of once daily dose.
5
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10. If patients experience any adverse events requiring discontinuation, the cost of dabigatran 
would be for only six months and then rivaroxaban for the following six months of the 
study period. 
11. Patients on both treatment options were assumed to have only 1 physician visit 
throughout the study period. In the physician visit the patients either get the referral to 
anticoagulant clinic for patients on warfarin, or to get annual prescriptions of dabigatran. 
12. Utility of patients treated with dabigatran was assumed to be similar to utility of those 
treated with ximelagatran, an older direct thrombin inhibitor due to the lack information 
about utility of patients on dabigatran. 
13. Adherence rates for both treatment alternatives were assumed to be similar due to 
insufficient data about adherence rate in patients on dabigatran. 
14. Willingness to pay (WTP) was set to be $50,000 as it is the most common value used in 
the economic analysis. 
Section 3.2: Outcome data 
The outcomes of this analysis were mainly obtained from the RELY clinical trial and 
supplemented by other literature (Table 3.1, 3.2). The probabilities of adverse events were based 
on data from the RELY clinical trial.
16
 Probabilities of MI for both treatment alternatives were 
obtained from an updated report of the RELY trial.
104
 Probability of being on the treatment with 
no change in the health state (well state) was calculated by subtracting sum of all the events 
probabilities in the tree from 1. Mortality rates of IS, ICH, GI bleeding, and MI were estimated 
from previous literature.
83
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Patient’s‎quality‎of‎life‎or‎utility‎may‎be‎affected‎by‎the‎type‎of‎anticoagulation‎therapy.‎
Dabigatran has advantages over warfarin as the patients do not require continuous monitoring, or 
food restriction and have fewer drug-drug interactions. The patients then may be less worried 
and concerned about treatment.
11
 On the other hand, warfarin is less expensive than dabigatran 
and had well established safety and efficacy profile.
11
 These‎factors‎may‎affect‎patients’‎
preferences toward one medication over another.  
 
Patient utilities for the different health states in the model were obtained from the published 
literature. Utility of AF patients treated with warfarin was based on a study that estimated the 
utility of AF patients treated with warfarin or aspirin.
105
 The time tradeoff and standard gamble 
methods were used to calculate utilities of 83 AF patients. In our study the mean utility for 
patients on warfarin therapy was used in the model. Due to lack of direct data regarding the 
utility of patients on dabigatran, it was estimated to be similar to utilities of those treated with 
ximelagatran, an older direct thrombin inhibitor, as seen in previous analysis.
106
 The utility of 
dabigatran patients was greater than patients on warfarin as the dabigatran does not require 
routine monitoring. By definition, utility of dead patients is zero. Utilities of patients 
experiencing IS, GI bleeding, ICH, MI, or dyspepsia were obtained from previous literature.
93,107
   
Section 3.3: Cost data 
In this analysis all direct medical costs associated with both treatment branches were added in 
the calculation (Table 3.3). The prices of the medicines (warfarin, dabigatran, and rivaroxaban) 
were obtained from Virginia Commonwealth University hospital database. The prices used were 
340B cost of the drugs.  The 340B cost is drug discount program applied to certain eligible 
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health care organizations and covered entities participating in the public health services such as 
Medicare/ Medicaid allow them to get the outpatients drugs at reduced prices from 
Manufacturers.
108
 The 340B cost was chosen in our model as they are considered a better 
estimate of drug cost for our targeted population (age >65 years old) who are eligible to 
Medicare.
109
  
 
According to American College of Cardiology (ACA)/American Heart Association (AHA) and 
the Heart Rhythm Society (HRS) guidelines for management of AF patients, the anticoagulation 
drug should be discontinued immediately and the patient carefully monitored if bleeding occurs.
5
 
In our study, if  bleeding develops for the patients on warfarin therapy, then warfarin would be 
immediately withdrawn and resumed after the bleeding is resolved, as the patients would still be 
at risk of developing stroke. For patients on dabigatran, it is recommended that when bleeding 
occurs that anticoagulation therapy discontinue and a new agent replace dabigatran.
110
 In our 
study, we assumed that rivaroxaban would replace dabigatran after treating the bleeding. 
Rivaroxaban was chosen because it has a good safety and efficacy profile and it is taken once 
daily.  
 
The cost of an anticoagulant clinic was derived from a study that estimated the quality and costs 
associated with 3 different anticoagulant clinics: pharmacist-managed, nurse-managed, and both 
pharmacist and nurse-managed anticoagulant clinics.
111
 In this study costs were broken into 3 
parts: labor expense, lab expense, and overhead cost. In our analysis we used estimates from 
pharmacist-managed anticoagulant clinics as we are more interested in the pharmacist role in 
these clinics. The annual cost per patient associated with pharmacist managed anticoagulant 
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clinic, adjusted to 2014, was $423. The majority of the cost was related to laboratory tests. The 
cost of a physician visit was obtained from blue book (physician office visit level 3) for both 
treatments.
112
 It was assumed patients in both branches have only 1 physician visit at the 
beginning of the treatment for either referral to anticoagulant clinic or an annual prescription for 
dabigatran. 
 
The cost of treating each event was obtained from Healthcare Cost and Utilization Project 
(HCUP) by using relevant Diagnosis-Related Group codes (DRG) (Table 3.4).
113
 The cost of 
fatal MI was based from HCUP by using the associated DRG code of fatal MI (DRG 283). Due 
to lack of DRG and ICD-9 codes for fatal IS, ICH, and GI bleeding, it was assumed that the cost 
of death associated with these events is similar to cost of death from any cause which was 
estimated from Shah SV, et al study.
97
 In that study, the researchers assumed that the cost of 
death from any cause was equal to $10,000. Because this number is considered reasonable when 
comparing it to cost of fatal MI, it was used in our analysis as cost of death from any cause, fatal 
IS, fatal ICH, or fatal GI bleeding. 
 
All the costs, from different years, where inflated to 2014 $US by using the US Healthcare 
inflation rate from Bureau of Labor Statistics.
114
 Because the time horizon of this study is 
assumed to be 1 year, there was no need for discounting costs and outcomes.
100
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Section 3.4: Sensitivity analysis 
Due to the uncertainty of the input values in the model, several sensitivity analyses were 
performed. Sensitivity analysis allows us to test the impact of uncertainty of the estimate values 
and model assumptions and how it affects the result of the analysis. The more similar the results 
of sensitivity analysis to the base case results, the greater the confidence we will have in our 
analysis. 
 
One way sensitivity analysis was performed on all the probability, utility and cost variables over 
plausible ranges presented in Table (3.1, 3.2, and 3.3). The values of ranges were obtained from 
previous literature by using 95% CI if available, or by calculating a range of 20% in each 
direction.  
 
The 95% confidence interval (CI) of anticoagulant clinic cost was calculated by using Standard 
Deviation (SD) of the mean cost that was reported by the Menzin study and applying it to 
equation 3.1.
111
 The calculated range was used then in the sensitivity analysis. Ranges of the cost 
of death were derived from Shah, et al. 
97
 Standard Errors (SE) of mean cost for each event (MI, 
fatal MI, GI bleeding, ICH, and IS) were used to calculate 95% CI by applying equation 3.1. The 
Healthcare inflation rate was also applied to SD, SE, and estimated range of death to convert 
them to 2014 $US. 
95%CI=                 Equation 3.1 
 
Depending on the severity of dyspepsia, sometime patient will only be managed by anti-ulcer on 
an outpatient basis without the need of admission. For this reason the lower limit of the range 
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used in the sensitivity analysis for dyspepsia was set to be $10. The upper limit of dyspepsia 
range was calculated by using the SE of mean cost reported by HCUP. 
 
Due to the different findings regarding probabilities of developing MI in both treatment 
strategies between RELY trial and FDA study , probabilities from the FDA study were used as 
the upper limit in our sensitivity analysis, while the lower limit was estimated to be 20% below 
the base case value.  
 
For the remaining variables, ranges were calculated by varying estimates by ±20%, due to lack 
of reporting 95% CI.   
 
In addition two way sensitivity analysis was performed between cost of warfarin and cost of 
dabigatran. Two way sensitivity analysis allow us to demonstrate impact of the two variables 
when changing their values simultaneously within given ranges. 
 
Moreover, Monte-Carlo probabilistic sensitivity analysis was performed, specifically second 
order simulation (parameter level), to simultaneously address uncertainty in all the variables in 
the model. Monte-Carlo allows us to calculate means of the cost, effectiveness and net monetary 
benefits of each treatment option. In this study, 10,000 simulations were conducted on all the 
variables. Each variable was defined based on certain distribution functions and a specific value 
of its mean and SD. The beta distribution was used for events probabilities and utilities as it 
ranged between 0-1. Gamma distribution was used for all cost variables. Mean of distribution for 
each variable was assumed to equal the base case input value in the model. SD for distribution of 
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each estimate in the model was equal to standard error (SE) that was calculated using following 
equation:  
SE= 
     
      
   Equation 3.2 
 
This equation used upper limit (UL) and lower limit (LL) based on range values used in the 
sensitivity analysis. 
115
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 40 
 
Figure 3.1: Schematic representation of the model 
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Table 3.1: Base-case probabilities values and ranges used in sensitivity analyses 
Variable Base case Probabilities ranges used in the 
sensitivity analysis 
Reference No. 
Minimum Maximum 
Dabigatran: 
     Dyspepsia  0.113 0.0904 0.1356 
16
 
     GI bleeding 0.0151 0.01208 0.01812 
16
 
     ICH 0.003 0.0024 0.0036 
16
 
     IS 0.0092 0.00736 0.01104 
16
 
     MI 0.0081 0.00648 0.0157 
16,104
 
     Death 0.0364 0.02912 0.04368 
16
 
Warfarin: 
     Dyspepsia  0.058 0.0464 0.0696 
16
 
     GI bleeding 0.0102 0.00816 0.01224 
16
 
     ICH 0.0074 0.00592 0.00888 
16
 
     IS 0.012 0.0096 0.0144 
16
 
     MI 0.0064 0.00512 0.0169 
16,104
 
     Death 0.0413 0.03304 0.04956 
16
 
Mortality:     
     GI bleeding 0.072 0.0576 0.0864 
83
 
     ICH 0.179 0.1432 0.2148 
83
 
     IS 0.082 0.0656 0.0984 
83
 
     MI 0.166 0.1328 0.1992 
83
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Table 3.2: Base-case utilities values and ranges used in sensitivity analyses 
Variable Base case Utilities ranges used in the sensitivity 
analysis 
Reference 
No. 
Minimum Maximum 
AF patient on 
warfarin  
0.987 0.7896 1 
105
 
AF patient on 
Dabigatran 
0.994 0.7952 1 
106
 
Dyspepsia  0.996 0.7968 1 
107
 
Non-fatal IS 0.61 0.488 0.732 
107
 
Non-fatal MI 0.87 0.696 1 
107 
Non-fatal ICH 0.39 0.312 0.468 
93
 
Non-fatal GI 0.94 0.752 1 
107
 
Death  0 0 0  By 
definition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
 
Table 3.3: Base-case cost values and ranges used in sensitivity analyses 
Variable Base case 
($) 
Cost ranges used in the sensitivity 
analysis 
Reference 
No. 
Minimum ($) Maximum ($) 
Warfarin(per year) 11 9 14 
VCU hospital 
Dabigatran (per year) 1,162 930 1,394 
VCU hospital
 
Rivaroxaban (per 6 
months) 
780 624 936 
VCU hospital 
Anticoagulant clinic 423 148 698 
111
 
Physician visit 139 111 167 
112 
Dyspepsia (DRG 391) 9,737 9,495 9,978 
113 
Non-fatal GI 
(DRG 377) 
14,169 13,862 14,477 
113
 
Non-fatal IS 
(DRG 61) 
25,435 24,457 26,413 
113
 
Non-fatal ICH 
(DRG 64) 
15,628 15,246 16,009 
113
 
Non-fatal MI 
(DRG 280) 
13,997 13,683 14,310 
113
 
Fatal MI 
(DRG 283) 
15,222 14,634 15,810 
113 
Death  10,908 0 21,815 
97
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Table 3.4: DRG codes and corresponding definitions 
DRG code Definition  
DRG 391 Esophagitis, gastrointestinal & misc. digest disorders w mcc* 
DRG 377 GI hemorrhage w mcc* 
DRG 61 Acute ischemic stroke w use of thrombolytic agent w mcc* 
DRG 64 Intracranial hemorrhage or cerebral infarction w mcc* 
DRG 280 Acute myocardial infarction, discharged alive w mcc* 
DRG 283 Acute myocardial infarction, expired w mcc* 
*w mcc: with major comorbidity\complication 
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Chapter IV: Results 
Section 4.1: Base case analysis 
In the base case analysis warfarin therapy in an anticoagulant clinic resulted in lower QALYs 
with a value of 0.934, while 150 mg BID dabigatran resulted in 0.948 QALYs (Table 4.1). Total 
costs were $2,222 for warfarin therapy supported by anticoagulation clinic management, and 
$3,394for dabigatran provided according to standard of care. Therefore, dabigatran resulted in a 
gain of 0.014 QALYS at an additional cost of $1,172. The ICERs for dabigatran compared with 
warfarin therapy was $82,793 per QALY saved (Note: 1,172/0.014 will not equal 82,793 due to 
rounding issue). 
 
Based on willingness to pay threshold of $50,000 per QALY saved, the ICER for dabigatran is 
not considered to be cost effective, so warfarin treatment provided as part of pharmacist-
managed anticoagulant clinic is considered more cost effective.   
 
In addition to ICER, the Net Monetary Benefit (NMB) is another method that can be used to 
determine the cost effective strategy. The value of NMB enables us to choose the most cost 
effective strategy based on the combination of cost, effectiveness and willingness to pay. The 
NMB is the difference between the monetary value of effectiveness measure (expected QALYs 
multiplied by the WTP value) and total expected costs (equation 4.1).
116
 The advantage of NMB 
is that it enables us to quantify the net benefit (in term of money) for each strategy.
117
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It is calculated by converting the effectiveness (in our case QALYs) into monetary value by 
multiplying it by WTP, and then subtracted from cost associated with the strategy (equation 
4.1).
118
 The strategy with the higher NMB is the most cost effective one. Based on our analysis 
warfarin therapy with an anticoagulant clinic is cost effective compare to dabigatran as it has 
higher NMB value compared to dabigatran ($44,471 for warfarin vs. $44,006 for dabigatran). 
The NMB is considered a better method, compared to ICER, to determine cost effectiveness 
strategy‎when‎there‎are‎small‎differences‎in‎effectiveness‎(as‎in‎our‎analysis‎ΔQALYs=0.014).118 
Another advantage of NMB over ICER is that it helps us to rank strategy from most cost 
effective to least.
119
   
NMB = (E × WTP) – C (Equation 4.1) 
(Where E = effectiveness; WTP = willingness-to-pay threshold; C = cost) 
 
NMB (for warfarin within anticoagulant clinic) = (0.934×$50,000) – $2,222= $44,471 
NMB (for dabigatran 150mg BID) = (0.948 ×$50,000) – $3, 394 = $44,006 
Section 4.2: One-way and two-way sensitivity analyses 
A tornado diagram (figure 4.3) is a bar chart of the results of a series of one-way sensitivity 
analyses which illustrate the variables with the most impact on the results of the model. The most 
influential cost variables were cost of death, cost of dyspepsia and cost of anticoagulant clinic. 
Important outcomes in the model were the probability of death associated with warfarin and 
utility values of AF patients on warfarin and utilities for dyspepsia. 
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Based on the tornado diagram, one way sensitivity analyses were done for the most influential 
variables with the higher impact on the model over plausible ranges. Varying the utilities of AF 
patients on warfarin had an impact on ICER value. If the value for utility of patients on warfarin 
was 0.947 or lower, the ICER value for dabigatran will be lower than WTP, and so the results 
will be favored toward dabigatran (Table 4.2). Net Benefit (NB) graph enable us to identify 
exactly threshold in which below it the result will change. The NB graph demonstrates the one 
way sensitivity analysis, in term of NMB. The NB graph is combination of effectiveness, cost 
and the willingness to pay (presented as NMB on y axis). In this graph the net monetary benefit 
(NMB) is being analyzed as a variable, while the values of utility of warfarin patient being 
change over the plausible range. The strategy with the higher net benefits is the more cost 
effective. When running the sensitivity analysis, the model will be recalculate five times over the 
plausible range of utility of warfarin patient (4 intervals) (Table 4.3).
120
 The values in the table 
(4.3) is then plotted to give us NB graph. NB Graph (Figure 4.4) tells us that if the utility of AF 
patients on warfarin is 0.976 or lower then it is a better to choose dabigatran therapy, and vice 
versa. For the utility of dyspepsia, changing the inputs values over the plausible range did not 
differ from the base case results. 
 
A one way sensitivity analysis was also conducted on cost of death and the results were almost 
similar to the base case analysis. Moreover, varying values of cost of anticoagulant clinic over 
their 95% CI did not influence the ICER values of dabigatran compared to warfarin therapy from 
the base case analysis. On the other hand, changing the values of cost of dyspepsia over plausible 
ranges had an impact on the ICER value (Table 4.4). NB graph for one way sensitivity analysis 
of cost of dyspepsia shows that if the cost for treating dyspepsia was $1,294 or less then 
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dabigatran will be more cost effective strategy compared to warfarin within anticoagulant clinic 
(Figure 4.5). 
 
Another one way sensitivity analysis was performed for the probability of death associated with 
warfarin therapy over ±20% range, and result indicates that it did have an impact over ICER 
value (Table 4.5). When the probability of death associated with warfarin reaches 0.049 or 
higher, then the results will be favored to dabigatran to be cost effective compared to warfarin 
(Figure 4.6) 
 
Finally, due to the differences between RELY trial and FDA study regarding probabilities of 
developing MI on both strategies, a one way sensitivity analysis was conducted by varying 
values of probability of MI for dabigatran and then for warfarin over plausible ranges to include 
the same probability value from FDA study. Both sensitivity analyses were similar to base case 
analysis. 
 
The two-way sensitivity analysis for the cost of warfarin and the cost of dabigatran indicated that 
warfarin treatment within pharmacist-managed anticoagulant clinic is dominated over dabigatran 
150mg BID over their plausible ranges.  
Section 4.3: Probabilistic sensitivity analysis 
The mean cost, effectiveness, and NMB of each strategy derived from Monte Carlo simulation 
were almost similar to the base case analysis (Table 4.6). Using a WTP threshold of $50,000 per 
QALY gained, almost 86.75% of calculations prefer treatment with the warfarin in anticoagulant 
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clinics compared to 13.25% of the simulation to dabigatran 150mg (figure 4.7). These 
percentages agree with our base case analysis. Moreover, we can be more confident by looking 
at the cost effectiveness acceptability curve and by setting a range of WTP between 0 to 
$100,000.This graph tells us the percentage of iterations that prefer each strategy based on 
different values of WTP. Looking at acceptability curve (figure 4.8), even when WTP set to 
$100,000 still treatment of warfarin in anticoagulant clinic is preferred compared to Dabigatran 
therapy. 
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Figure 4.1: Schematic representation of model with base case results 
 
 
 
 
$2,222/0.934 QALY 
$3,394/0.948 QALY 
 51 
 
Table 4.1: Base case results 
Strategy Cost 
($) 
Incremental cost 
($) 
Effectiveness 
(QALY) 
Incremental 
effectiveness 
(QALY) 
Cost/effectiveness 
 
ICER* 
($/QALY) 
NMB** 
($) 
Warfarin in 
anticoagulant 
clinic 
2,222   0.934   2,379   44,471 
Dabigatran 
150mg BID 
3,394 1,172 0.948 0.014 3,581 82,793*** 44,006 
*ICER: Incremental cost effectiveness ratio 
**NMB: Net Monetary Benefit 
***Note: 1,172/0.014 will not equal 82,793 due to rounding issue
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Table 4.2: One way sensitivity analysis results for utility of AF patients on warfarin 
Utility of AF 
patients on 
warfarin 
Strategy Cost 
($) 
Incremental cost 
($) 
Effectiveness 
(QALY) 
Incremental 
effectiveness 
(QALY) 
ICER* 
($/QALY) 
NMB** 
($) 
0.7896 Warfarin in 
anticoagulant 
clinic 
2,222 0.00 0.763 0.00 0.00 35,936 
Dabigatran 
150mg BID 
3,394 1,172 0.948 0.185 6,342 44,006 
0.8422 Warfarin in 
anticoagulant 
clinic 
2,222 0.00 0.809 0.000 0.000 38,210 
Dabigatran 
150mg BID 
3,394 1,172 0.948 0.139 8,412 44,006 
0.8948 Warfarin in 
anticoagulant 
clinic 
2,222 0.00 0.854 0.000 0.000 40,484 
Dabigatran 
150mg BID 
3,394 1,172 0.948 0.094 12,488 44,006 
0.9474 Warfarin in 
anticoagulant 
clinic 
2,222 0.00 0.900 0.000 0.000 42,759 
Dabigatran 
150mg BID 
3,394 1,172 0.948 0.048 24,222 44,006 
1.0 Warfarin in 
anticoagulant 
clinic 
2,222 0.00 0.945 0.000 0.000 45,033 
Dabigatran 
150mg BID 
3,394 1,172 0.948 0.003 401,533 44,006 
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Table 4.3: Net Benefit table for sensitivity analysis of utility of warfarin patients 
Value of utility of warfarin 
patient 
Net Monetary Benefit (NMB) ($) 
Warfarin within anticoagulant 
clinic  
Dabigatran 150 mg BD 
0.790 35,936 44,006 
0.842 38,210 44,006 
0.895 40,484 44,006 
0.947 42,759 44,006 
1.000 45,033 44,006 
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Table 4.4: Net Benefit table for sensitivity analysis of cost of dyspepsia 
Cost of 
dyspepsia 
($) 
Strategy Cost 
($) 
Incremental cost ($) Effectiveness 
(QALY) 
Incremental 
effectiveness 
(QALY) 
ICER* 
($/QALY) 
NMB** 
($) 
10 Warfarin in 
anticoagulant 
clinic 
1,658 0.00 0.934 0.00 0.00 45,035 
Dabigatran 
150mg BID 
2,295 637 0.948 0.014 45,014 
 
 
45,105 
2,502 Warfarin in 
anticoagulant 
clinic 
1,802 0.00 0.934 0.000 0.000 44,891 
Dabigatran 
150mg BID 
2,577 774 0.948 0.014 54,693 44,824 
4,994 
 
 
 
 
Warfarin in 
anticoagulant 
clinic 
1,947 0.00 0.934 0.000 0.000 44,746 
Dabigatran 
150mg BID 
2,859 912 0.948 0.014 64,372 44,542 
7,486 Warfarin in 
anticoagulant 
clinic 
2,091 0.00 0.934 0.000 0.000 44,601 
Dabigatran 
150mg BID 
3,140 1,049 0.948 0.014 74,051 44,261 
9,978 Warfarin in 
anticoagulant 
clinic 
2,236 0.00 0.934 0.000 0.000 44,457 
Dabigatran 
150mg BID 
3,422 1,186 0.948 0.014 83,730 43,979 
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Table 4.5: One way sensitivity analysis results for probability of death associated with warfarin therapy 
probability of 
death 
associated with 
warfarin 
therapy 
Strategy Cost 
($) 
Incremental cost 
($) 
Effectiveness 
(QALY) 
Incremental 
effectiveness 
(QALY) 
ICER* 
($/QALY) 
NMB** 
($) 
0.033 Warfarin in 
anticoagulant 
clinic 
2,132 0.00 0.942 0.00 0.00 44,968 
Dabigatran 
150mg BID 
3,394 1,262 0.948 0.006 210,128 44,006 
0.037 Warfarin in 
anticoagulant 
clinic 
2,177 0.00 0.938 0.000 0.000 44,719 
Dabigatran 
150mg BID 
3,394 1,217 0.948 0.01 120,725 44,006 
0.041 Warfarin in 
anticoagulant 
clinic 
2,222 0.00 0.934 0.000 0.000 44,471 
Dabigatran 
150mg BID 
3,394 1,172 0.948 0.014 82,793 44,006 
0.045 Warfarin in 
anticoagulant 
clinic 
2,267 0.00 0.93 0.000 0.000 44,222 
Dabigatran 
150mg BID 
3,394 1,127 0.948 0.018 61,817 44,006 
0.049 Warfarin in 
anticoagulant 
clinic 
2,312 0.00 0.926 0.000 0.000 43,973 
Dabigatran 
150mg BID 
3,394 1,082 0.948 0.022 48,505 44,006 
 
 
 
 56 
 
 
Table 4.6: Results of Monte Carlo probabilistic sensitivity analysis 
Attribute Statistics Warfarin with anticoagulant clinic Dabigatran 150mg BID 
Cost Mean  2224 3,421 
 SD* 297.58 276.6 
Effectiveness  Mean  0.934 0.948 
 SD* 0.047 0.041 
NMB** Mean  44,480 43,987 
 SD* 2,350.83 2,093.77 
*SD: Standard deviation 
**NMB: Net Monetary Benefit 
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Figure 4.2: Base case cost effectiveness graph 
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Figure 4.1: Tornado Diagram demonstrate influence of each variable on the base case results 
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Figure 4.4: Net benefit graph for one way sensitivity analysis for utility of AF patients on 
warfarin 
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Figure 4.5: Net benefit graph for one way sensitivity analysis for cost of dyspepsia 
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Figure 4.6: Net benefit graph for one way sensitivity analysis for probability of death associated 
with warfarin therapy 
 
 
 
 
 
 
 
 
 
 62 
 
Figure 4.7: Strategy selection chart demonstrate percentage of iterations that prefer each strategy 
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Figure 4.8: Cost effectiveness acceptability curves representing percentage of iterations that 
prefer each strategy according to different values of WTP 
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Chapter V: Discussion 
 
 
In this study we assessed cost effectiveness of Dabigatran 150mg BID compared to adjusted dose 
of warfarin within pharmacist-managed anticoagulant clinics. Dabigatran was chosen to 
represent NOACs, as it is the most studied NOAC and the first one introduced into the US 
market. According to this study, for AF patient‎age‎≥‎65‎years‎old‎with higher risk of stroke 
(CHADS2 score >2), it is more cost effective to treat them with warfarin within an anticoagulant 
clinic rather than dabigatran. The base case analysis showed that neither treatment was dominant. 
However, the ICER for dabigatran was over $82,000 per QALY saved exceeded the established 
WTP threshold of $50,000, making warfarin treatment at anticoagulant clinics a more cost 
effective option. Moreover, warfarin treatment resulted in higher net monetary benefits (NMB) 
compared to dabigatran therapy. The base case analysis revealed that for every 100 patients 
treated by dabigatran, there is almost a 1.4 QALY gained compared to those treated with 
warfarin and attending anticoagulant clinic. On the other hand, treatment with dabigatran cost 
approximately an extra $1,172 per patient compared to warfarin in anticoagulant clinic.  
This analysis was found to be sensitive to utility of patients on warfarin, which determined by 
control of INR levels and time spent within therapeutic INR ranges. It suggested that if the utility 
of warfarin patient dropped lower than 0.947, then the results will change and be to favor 
dabigatran compare to warfarin.
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Also the sensitivity analysis indicates that cost of treating dyspepsia and probability of death 
associated with warfarin therapy have an impact on the ICER value. 
 
Moreover, the analysis revealed that the cost of anticoagulant clinic did not have an impact on 
the overall findings. Varying cost of anticoagulant clinic over plausible ranges did not decrease 
the ICER associated with dabigatran below WTP threshold ($50,000/QALY). This is considered 
interesting finding, as it addressed a crucial component of our research. In this analysis, we were 
trying to assess importance of anticoagulant clinic after introduction of NOACs. Based on this 
result, despite the fact that NOACs provide a greater QALYs compared to warfarin, they may 
not represent an acceptable economic value. In other words, the relative advantage of NOACs 
over the warfarin depends mainly on quality of control of warfarin therapy and how well it is 
managed. Basically, the important factor that can affect the preferred treatment option is not the 
cost of anticoagulant clinic associated with warfarin therapy, but the level of INR control and the 
impact‎on‎quality‎of‎patients’‎life. 
 
In most previous studies, cost effectiveness analyses have concluded that dabigatran is more cost 
effective compared to warfarin.  Freeman et al. reported that dabigatran may be cost effective 
compared to warfarin within ICER value of $45,372 per QALY gained with dabigratran.
88
 A 
model by Kamal et al. yielded a similar conclusion with an ICER estimate of $25,000 per QALY 
gained for dabigatran.
93
 Shah et al. estimated an ICER of $86,000 per QALY gained for 
dabigatran compared to warfarin.
97
  
 
 66 
 
The primary difference between the conclusions in this analysis and similar published economic 
studies resulted from assumptions about the patient population being treated. They all concluded 
that dabigatran is only cost effective if the INR control is poor.
93,97
 In these two studies (by Shah 
et al. and Kamal et. Al.) they incorporated time in therapeutic range as a variable in their 
sensitivity analysis and found that that INR control had impact on the base case findings. This 
means that warfarin might be more economical if the INR control is excellent, which may be the 
case with most of anticoagulant clinics.
10,121
  
 
There are other reasons why our results differed in finding that warfarin treatment with 
anticoagulant clinic is preferred over dabigatran for AF patients with higher risk of stroke.  One 
reason is that our analysis used a decision tree with a time period of one year, while other studies 
used Markov models assessing lifetime outcomes and costs. The cost calculation and the 
probabilities of developing any adverse event can be affected by the time horizon of the study. 
Also the type of economic model used to analyze data can have an impact over the result due to 
the differences in the underlined assumptions and model design. 
 
Another reason is that in our study we assumed that patients treated with warfarin would be 
within therapeutic range and have excellent INR control for all the study period.  Most of the 
previously discussed studies reported that their results will only be applicable if the INR control 
was poor. This is because the efficacy and the safety of warfarin therapy depend mainly on the 
level of INR control and the time spent within therapeutic ranges.  
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Previous to the appearance of NOACs, studies of anticoagulant clinics showed them to be 
significantly better at controlling anticoagulation than usual care.
29,31,40,54,61,72
  For example, 
Nichol et al. showed that time spent in therapeutic ranges was significantly longer for the 
patients attending pharmacist-managed anticoagulant clinics compared to usual care (68.14% vs. 
42.07%, p<0.001).
61
  Therefore, NOACs are likely to be economically superior if warfarin is not 
monitored in anticoagulation clinics or some other similar program.  
 
In addition to the findings of this study, there are other reasons to limit its use in replacing 
warfarin in real world practice. One is that most evidence for its use comes from specific 
populations of‎AF‎patients‎≥65‎years‎old‎with‎no‎renal‎failure‎disorder;‎while‎in‎the‎real‎world‎
most of the AF patients are 75 and older with renal disorder and other complications.
122
 Some 
clinicians still hesitate of prescribing dabigatran in those patients without clinic evidence of 
effectiveness and safety.
123
 Moreover, most AF patients are elderly with chronic conditions and 
are maintained on warfarin, which make it difficult to replace with new drug like dabigatran. In 
practice, NOACs are dispensed more often for deep vein thrombosis (DVT) patients as they are 
relatively younger and do not usually need chronic use of medications.   
 
There is a crucial need for real world data treatments for AF patients. Each AF patient in real 
practice is unique and choice‎of‎the‎appropriate‎drug‎depends‎on‎numerous‎factors:‎patient’s‎
clinical‎conditions,‎clinician‎and‎patient’s‎preference,‎and‎cost.5 There are several guidelines for 
selecting appropriate anticoagulant agents such as AHA/ACC/HRS Guideline for the 
management of patients with AF. However, there is scarce clinical information for appropriate 
management of major bleeding specially with NOACs. Moreover there is no clear guideline of 
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when to switch to another agent and what type of agent. This is can be due to complexity of AF 
patients, and that each scenario could be treated with different way. 
 
In this study we were able to show that anticoagulant clinics are still economically viable after 
the introduction of NOACs. Anticoagulant clinics are still needed to monitor warfarin treatments 
for AF patients who may not benefit from NOACs.  
 
There are several limitations of our study that need to be addressed. First, all of the event 
probabilities where derived from a single clinical trial. This is because the RELY trial is the only 
published clinical trial that directly compared warfarin and dabigatran. We tried to test this 
limitation by using some data in our sensitivity analyses from an FDA study report that looked at 
adverse events probabilities between dabigatran and warfarin. Second, we assumed that 
pharmacist-managed anticoagulant clinics were able to keep INR for all warfarin patients within 
therapeutic ranges similar to those in the RELY study. In the real world the percentage of INR 
control and time spent in the therapeutic range varies. Estimates of anticoagulant clinic patients 
within therapeutic ranges vary from 50.2-68.14%, while the patients in the RELY clinical trial 
(64%). 
16,29,40,61
 This can have an impact on our results as we might overestimate effectiveness of 
patients in anticoagulant clinic. Third, we assumed that all patients in both treatment options had 
the same medication adherence rates. This might differ from the real world, because each option 
differed in dosage regimen, safety profile, and monitoring. This assumption was made because 
there was insufficient data regarding level of adherence of NOACs in real world. This is can be 
due to the fact that NOACs are still considered new and there are smaller numbers of patients 
treated with them compared to those treated with warfarin.  One point that we can add here is 
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that because dabigatran patients were not followed in anticoagulants services, they may have 
lower adherence rate compare to those on warfarin and attend anticoagulant clinic. This can 
impact on our results as we might overestimate effectiveness of dabigatran in real world. 
Another limitation of the study is that we assumed that rivaroxaban would replace dabigatran in 
case of developing major bleeding. This assumption was made due to limited clinical 
information for appropriate management of major bleeding specially with NOACs. Moreover, 
although this study was done from societal perspective, we only captured direct medical cost 
associated with each treatment option. In this analysis, the long term effect of both treatments 
was not addressed as our time horizon was only for one year. This is due to the lack of data 
regarding long term effect of the NOACs. Finally, as the case with most of this type of analysis, 
data were driven from different sources; however we tried to answer this by running multiple 
sensitivity tests. 
 
In conclusion, warfarin treatment associated with pharmacist-managed anticoagulant clinic is an 
economically‎viable‎strategy‎for‎AF‎patients‎age‎≥65 years old and with higher risk of stroke 
(CHADS2 score‎≥2). This result is highly affected by patient utility preferences for warfarin 
treatment, which determined by control of INR levels and time spent within therapeutic INR 
ranges. Based on the results, there is a need to focus on improving the role of pharmacist in these 
clinics and try to recruit more of AF patient to attend the anticoagulant clinic in order to enhance 
therapeutics outcomes and reduce complications associated with warfarin treatment. Because this 
model is built upon clinical trial data, future studies may be needed to assess effectiveness and 
safety of NOACs compared to warfarin within anticoagulant clinic in real world settings.   
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Appendix A 
 
Figure A.1: Schematic representation of model with payoffs 
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Appendix B 
 
Table B.1: Resource utilized and cost associated with each branch in the descion tree for warfarin patients within 
pharmacist-managed anticoagulant clinic 
 
Path of each branch in 
the tree 
Cost of 
warfarin 
(per year) ($) 
Cost of 1 
physician visit 
($) 
Cost of 
anticoagulant 
clinic ($) 
Cost of treating 
adverse event 
($) 
Total cost  
($) 
Well state 11 139 423 - 573 
Non-fatal IS 11 139 423 25,435 26,008 
Fatal IS 11 139 423 10,908 11,481 
Non-fatal ICH 11 139 423 15,628 16,201 
Fatal ICH 11 139 423 10,908 11,481 
Non-fatal GI bleeding 11 139 423 14,169 14,742 
Fatal GI bleeding 11 139 423 10,908 11,481 
Non-fatal MI 11 139 423 13,997 14,570 
Fatal MI 11 139 423 15,222 15,795 
Dyspepsia  11 139 423 9,737 10,310 
Death from any cause 11 139 423 10,908 11,481 
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Table B.2: Resource utilized and cost associated with each branch in the decision tree for dabigatran patients 
 Path of each branch 
in the tree 
Cost of 
dabigatran 
(per year) 
($) 
Cost of 
dabigatran  
(6 months) 
($) 
Cost of 
rivaroxaban 
(6 months) 
 ($) 
Cost of 1 
physician 
visit   
($) 
Cost of 
treating 
adverse event 
($) 
Total cost 
 ($) 
Well state 1,162 - - 139 - 1,301 
Non-fatal IS 1,162 - - 139 25,435 26,736 
Fatal IS 1,162 - - 139 10,908 12,209 
Non-fatal ICH - 581 780 139 15,628 17,128 
Fatal ICH 1,162 - - 139 10,908 12,209 
Non-fatal GI 
bleeding 
- 581 780 139 14,169 15,669 
Fatal GI bleeding 1,162 - - 139 10,908 12,209 
Non-fatal MI 1,162 - - 139 13,997 15,298 
Fatal MI 1,162 - - 139 15,222 16,523 
Dyspepsia  1,162 - - 139 9,737 11,038 
Death from any 
cause 
1,162 - - 139 10,908 12,209 
